Market Pulse
Daily · Oct 7, 2026 · data.go.kr + ECOS
KOSPI
6,803.90
-137.49 (-1.98%)
KOSDAQ
898.43
-21.49 (-2.34%)
KOSPI 200
1,073.63
-22.20 (-2.03%)
USD/KRW
1,338.50
128940KOSPI·May 27, 2026
Initiating Coverage: Core Business Recovery; Obesity, R&D Next
KB Securities published a company analysis report on Hanmi Pharm. Co., Ltd. (128940) titled "Initiating Coverage: Core Business Recovery; Obesity, R&D Next".
Summary
Covers Hanmi Pharm. Co., Ltd. (128940).
Covered stock
More on 128940
Roche��s answer to Eli Lilly and Novo NordiskMirae Asset Securities · Aug 26, 2026Focus on Beijing Hanmi��s recovery and pipeline progressMirae Asset Securities · Jul 29, 2026Eli Lilly deal adds to pipeline valueMirae Asset Securities · Jun 04, 2026Sailing With LillyKB Securities · Jun 02, 2026First Korean pharma to translate the obesity theme into earningsMirae Asset Securities · Feb 06, 20262Q25 review: Revenue misses, OP beatsMirae Asset Securities · Jul 29, 2025Focus on potential recovery in quarterly earnings and June ADA eventMirae Asset Securities · Feb 05, 2025